Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Clin Trials. 2013 Oct 3;11(2):246–262. doi: 10.1177/1740774513498322

Table 6. Population-averaged responses (proportions), relative risks, and risk differences of the 12 Antimanic drugs.

ARI CAR HAL LAM LIT OLA PLA QUE RIS TOP VAL ZIP
ARI 0.50 (0.44,0.57) 0.96 (0.72,1.37) 0.90* (0.75,1.08) 0.95 (0.61,2.24) 0.92 (0.75,1.13) 0.90 (0.75,1.07) 1.37 (1.17,1.59) 0.93 (0.77,1.12) 0.92 (0.76,1.11) 2.33 (1.05,6.54) 0.96 (0.78,1.17) 1.06 (0.86,1.33)
CAR -0.02 (-0.18,0.15) 0.53 (0.38,0.68) 0.94* (0.66,1.26) 0.99 (0.58,2.38) 0.96 (0.67,1.30) 0.94 (0.66,1.24) 1.43 (1.01,1.86) 0.97 (0.68,1.29) 0.96 (0.67,1.27) 2.43 (1.03,6.90) 1.00 (0.70,1.34) 1.11 (0.76,1.51)
HAL -0.05* (-0.15,0.04) -0.03* (-0.20,0.13) 0.56 (0.48,0.64) 1.05* (0.67,2.49) 1.02* (0.82,1.25) 1.00 (0.83,1.18) 1.52 (1.29,1.77) 1.03* (0.85,1.24) 1.02 (0.84,1.22) 2.59 (1.16,7.26) 1.06* (0.86,1.30) 1.17* (0.95,1.46)
LAM -0.03 (-0.31,0.29) -0.00 (-0.32,0.33) 0.03* (-0.26,0.34) 0.53 (0.23,0.81) 0.96 (0.41,1.53) 0.94* (0.40,1.48) 1.44 (0.61,2.24) 0.97 (0.41,1.53) 0.97* (0.41,1.52) 2.41 (0.76,7.37) 1.00 (0.42,1.59) 1.11 (0.47,1.78)
LIT -0.05 (-0.15,0.06) -0.02 (-0.20,0.15) 0.01* (-0.11,0.12) -0.02 (-0.33,0.27) 0.55 (0.46,0.64) 0.98 (0.80,1.19) 1.49 (1.24,1.78) 1.01 (0.83,1.24) 1.00 (0.81,1.23) 2.54 (1.13,7.14) 1.04 (0.84,1.29) 1.15 (0.92,1.47)
OLA -0.06 (-0.15,0.04) -0.03 (-0.20,0.13) -0.00 (-0.10,0.09) -0.03* (-0.34,0.26) -0.01 (-0.12,0.10) 0.56 (0.49,0.63) 1.52 (1.33,1.75) 1.03 (0.86,1.24) 1.02 (0.86,1.22) 2.60 (1.17,7.30) 1.07* (0.89,1.28) 1.18* (0.96,1.46)
PLA 0.14 (0.06,0.21) 0.16 (0.00,0.31) 0.19 (0.11,0.27) 0.16 (-0.14,0.45) 0.18 (0.09,0.27) 0.19 (0.12,0.26) 0.37 (0.33,0.41) 0.68 (0.58,0.80) 0.67 (0.57,0.79) 1.70 (0.77,4.80) 0.70 (0.59,0.83) 0.77 (0.65,0.94)
QUE -0.04 (-0.14,0.06) -0.02 (-0.18,0.15) 0.01* (-0.09,0.12) -0.01 (-0.33,0.28) 0.00 (-0.10,0.12) 0.02 (-0.08,0.12) -0.18 (-0.26,-0.10) 0.55 (0.47,0.62) 0.99 (0.82,1.20) 2.53 (1.13,7.06) 1.03 (0.84,1.27) 1.14 (0.93,1.43)
RIS -0.05 (-0.15,0.05) -0.02 (-0.19,0.14) 0.01 (-0.10,0.11) -0.02* (-0.33,0.27) -0.00 (-0.12,0.12) 0.01 (-0.09,0.11) -0.18 (-0.26,-0.10) -0.01 (-0.11,0.10) 0.55 (0.48,0.63) 2.55 (1.14,7.16) 1.04* (0.85,1.28) 1.15* (0.93,1.44)
TOP 0.29 (0.02,0.45) 0.31 (0.02,0.51) 0.34 (0.07,0.51) 0.31 (-0.09,0.63) 0.33 (0.06,0.50) 0.34 (0.08,0.50) 0.15 (-0.11,0.30) 0.33 (0.06,0.49) 0.33 (0.06,0.50) 0.22 (0.08,0.48) 0.41 (0.15,0.91) 0.45* (0.16,1.02)
VAL -0.02 (-0.13,0.08) -0.00 (-0.17,0.17) 0.03* (-0.08,0.14) 0.00 (-0.31,0.29) 0.02 (-0.09,0.14) 0.03* (-0.07,0.13) -0.16 (-0.25,-0.08) 0.02 (-0.10,0.13) 0.02* (-0.09,0.13) -0.31 (-0.48,-0.05) 0.53 (0.45,0.62) 1.11 (0.89,1.40)
ZIP 0.03 (-0.08,0.13) 0.05 (-0.12,0.22) 0.08* (-0.03,0.19) 0.05 (-0.26,0.35) 0.07 (-0.04,0.20) 0.09* (-0.02,0.19) -0.11 (-0.19,-0.03) 0.07 (-0.04,0.18) 0.07* (-0.04,0.18) -0.26* (-0.42,0.01) 0.05 (-0.06,0.17) 0.48 (0.39,0.56)

Drugs are reported in alphabetical order. Diagonal panels are the population-averaged response rate; upper triangular and lower triangular panels are the relative risks (RRs) and risk differences (RDs) of the first drug in alphabetical order compared with the second drug in alphabetical order, respectively. Drugs with higher response rate are more effective; RRs larger than 1.0 or positive RDs favor the first drug in alphabetical order. To obtain comparisons in the opposite direction, reciprocals should be taken for RR and opposite sign should be used for RD. Statistically significant results are in bold and underlined. Comparisons statistically significant here but not in Cipriani et al7. or vice versa are noted with *. For all summaries, we report both the Bayesian posterior medians and the 95% credible intervals. ARI=aripiprazole, CAR=carbamazepine, HAL=haloperidol, LAM=lamotrigine, LIT=lithium, OLA=olanzapine, PLA=placebo, QUE=quetiapine, RIS=risperidone, TOP=topiramate, VAL=valproate, and ZIP=ziprasidone.